Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Former Abbott Drug Unit Recalls Synthroid Again

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2013 | 09:36pm CET

Abbott Laboratories' (>> Abbott Laboratories) former pharmaceutical unit, now spun off as AbbVie Inc. (>> AbbVie Inc), recently recalled more than 28,520 bottles of the thyroid-hormone replacement therapy Synthroid over a dose mix-up, marking the second recall of the drug in six months.

One lot of 150-microgram Synthroid tablets was recalled because one bottle was found to contain lower-dose, 75-microgram tablets, AbbVie spokesman Gregory Miley said Friday. The voluntary recall was initiated in early December as a precaution, he said.

The cause was a "manufacturing line clearance error," he said, and AbbVie has taken corrective action. The company isn't aware of any increase in patient complaints or adverse events associated with the label error.

AbbVie was spun off to Abbott shareholders as an independent company at the start of January. AbbVie assumed Synthroid's U.S. marketing rights, though Abbott Labs continues to market the drug outside the U.S.

In July, Abbott recalled three lots of Synthroid because some bottles had defects that could affect the stability of the tablets at the end of shelf life. More than 136,500 bottles of Synthroid were subject to that recall, though Abbott said a majority of them remained under Abbott's control and weren't shipped out.

Both Synthroid recalls were classified by the FDA as Class II, which is typically applied in situations where a product might cause a temporary health problem or pose only a slight threat of a serious health problem.

Synthroid is a synthetic thyroid hormone used by people with hypothyroidism, in which the thyroid gland doesn't produce enough natural thyroid hormone.

Abbott reported $461 million of global Synthroid sales for the first nine months of 2012.

AbbVie shares were recently down a penny at $33.61.

Write to Peter Loftus at peter.loftus@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Abbott Laboratories, AbbVie Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
02:01p ABBOTT : Announces European Launch of the Proclaim(TM) DRG Neurostimulation Syst..
01/17 ABBOTT LABORATORIES : New Data Confirms Abbott's Dorsal Root Ganglion Stimulatio..
01/16 ABBOTT LABORATORIES : Global Prebiotics Market 2017 - Abbott Laboratories, GNC, ..
01/12 ABBOTT LABORATORIES : Announces U.S. Launch and First Commercial Use of the New ..
01/12 ABBOTT : Announces U.S. Launch and First Commercial Use of the New EnSite(TM) Pr..
01/12 ABBOTT LABORATORIES : Trademark Application for "FRUITIFIED" Filed by Abbott Lab..
01/12 ABBOTT LABORATORIES : Trademark Application for "ZONEPERFECT INDULGENCE" Filed b..
01/12 ABBOTT LABORATORIES : ' Trademark Application for "KNOWLEDGE LADDERS" Filed
01/12 ABBOTT LABORATORIES : $30,000 Federal Contract Awarded to Abbott Laboratories
01/11 ABBOTT LABORATORIES : CONTRACT AWARD - 65-- VA263-17-P-1520 Pros V23 618 295580 ..
More news
Sector news : Pharmaceuticals - NEC
01:40pDJELI LILLY AND : to Buy Migraine Drug Developer CoLucid Pharmaceuticals
12:08p Drugmakers in Davos shift focus to chronic diseases of poor
08:49aDJBayer Joins Jobs Parade -- WSJ
01:56aDJBAYER : Will Keep Monsanto Jobs in U.S., Trump Team Says -- 2nd Update
12:05aDJAllergan Admits to Disclosure Violations During Valeant Bid
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09:20a Valeant Gives Up Gains
08:53a Abbott launches new neurostimulation system in Europe
01/17 DGI FOR THE DIY : 2016 Portfolio Review
01/16 Bummed About Your Abbott Labs Dividend? Here's How To Boost It
01/16 Abbott Laboratories Increases Dividend Just 2%... What Now?
Advertisement
Financials ($)
Sales 2016 20 898 M
EBIT 2016 4 132 M
Net income 2016 1 666 M
Debt 2016 4 126 M
Yield 2016 2,53%
P/E ratio 2016 22,91
P/E ratio 2017 17,42
EV / Sales 2016 3,58x
EV / Sales 2017 3,35x
Capitalization 70 602 M
More Financials
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 46,7 $
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Senior VP-Finance
Randel W. Woodgrift VP-Vascular, Manufacturing, Research & Development
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES6.48%70 602
JOHNSON & JOHNSON-0.30%312 507
ROCHE HOLDING LTD.1.29%200 476
PFIZER INC.-1.29%194 551
NOVARTIS AG-2.70%185 185
MERCK & CO., INC.4.43%169 509
More Results